Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman

被引：39

作者：

Elter, Thomas

Sieniawski, Michal ^{[1
]}

Gossmann, Axel

Wickenhauser, Claudia

Schroeder, Ursula

Seifert, Harald

Kuchta, Johannes

Burhenne, Juergen

Riedel, Klaus-Dieter

Faetkenheuer, Gerd

Cornely, Oliver A.

机构：

[1] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany

[2] Univ Cologne, Dept Radiol, D-50924 Cologne, Germany

[3] Univ Cologne, Inst Pathol, D-50924 Cologne, Germany

[4] Univ Cologne, Clin Otorhinolaryngol Head & Neck Surg, D-50924 Cologne, Germany

[5] Univ Cologne, Inst Med Microbiol Immunol & Hyg, D-50924 Cologne, Germany

[6] Univ Cologne, Dept Neurosurg, D-50924 Cologne, Germany

[7] Univ Heidelberg, Dept Pharmacol & Pharmacoepidemiol, Heidelberg, Germany

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2006年 / 28卷 / 03期

关键词：

rhinocerebral aspergillosis; voriconazole level; intracerebral abscess;

D O I：

10.1016/j.ijantimicag.2006.04.006

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Invasive aspergillosis of the central nervous system has a mortality rate exceeding 90%. We describe a 29-year-old woman with a medical history of chronic polyarthritis who developed a proven rhinocerebral Aspergillus fumigatus infection refractory to first-line treatment with liposomal amphotericin B. The patient responded successfully to salvage combination treatment with voriconazole and caspofungin. Furthermore, for the first time, voriconazole levels in an intracerebral abscess were measured in this patient undergoing voriconazole oral therapy. (c) 2006 Elsevier B.V. and the International Society of Chemotherapy. All Rights reserved.

引用

页码：262 / 265

页数：4

共 16 条

[1] FUNGAL-INFECTIONS IN CANCER-PATIENTS - AN INTERNATIONAL AUTOPSY SURVEY [J].

BODEY, G ;

BUELTMANN, B ;

DUGUID, W ;

GIBBS, D ;

HANAK, H ;

HOTCHI, M ;

MALL, G ;

MARTINO, P ;

MEUNIER, F ;

MILLIKEN, S ;

NAOE, S ;

OKUDAIRA, M ;

SCEVOLA, D ;

VANTWOUT, J .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1992, 11 (02) :99-109

[2]

Boes B, 1994, J Neuroimaging, V4, P123

[3] TISSUE DISTRIBUTION AND BIOACTIVITY OF AMPHOTERICIN-B ADMINISTERED IN LIPOSOMES TO CANCER-PATIENTS [J].

COLLETTE, N ;

VANDERAUWERA, P ;

MEUNIER, F ;

LAMBERT, C ;

SCULIER, JP ;

COUNE, A .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 (04) :535-548

[4] TISSUE CONCENTRATIONS AND BIOACTIVITY OF AMPHOTERICIN-B IN CANCER-PATIENTS TREATED WITH AMPHOTERICIN-B-DEOXYCHOLATE [J].

COLLETTE, N ;

VANDERAUWERA, P ;

LOPEZ, AP ;

HEYMANS, C ;

MEUNIER, F .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (03) :362-368

[5] Therapeutic outcome in invasive aspergillosis [J].

Denning, DW .

CLINICAL INFECTIOUS DISEASES, 1996, 23 (03) :608-615

[6]

DENNING DW, 1990, REV INFECT DIS, V12, P1147

[7] Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872) [J].

Hajdu, R ;

Thompson, R ;

Sundelof, JG ;

Pelak, BA ;

Bouffard, FA ;

Dropinski, JF ;

Kropp, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2339-2344

[8] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].

Herbrecht, R ;

Denning, DW ;

Patterson, TF ;

Bennett, JE ;

Greene, RE ;

Oestmann, JW ;

Kern, WV ;

Marr, KA ;

Ribaud, P ;

Lortholary, O ;

Sylvester, R ;

Rubin, RH ;

Wingard, JR ;

Stark, P ;

Durand, C ;

Caillot, D ;

Thiel, E ;

Chandrasekar, PH ;

Hodges, MR ;

Schlamm, HT ;

Troke, PF ;

de Pauw, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415

[9]

Heykants J., 1987, Recent trends in the discovery, development and evaluation of antifungal agents., P223

[10]

Hoffman HL, 2002, EXPERT OPIN INV DRUG, V11, P409

← 1 2 →